Effects of recombinant human growth hormone in the treatment of dwarfism and relationship between IGF-1, IGFBP-3 and thyroid hormone

Ren,Shanxiang; Nie,Yuxiang; Wang,Aihong

doi:10.3892/etm.2016.3831

Effects of recombinant human growth hormone in the treatment of dwarfism and relationship between IGF-1, IGFBP-3 and thyroid hormone

Authors:
- Shanxiang Ren
- Yuxiang Nie
- Aihong Wang
View Affiliations

Affiliations: Department of Pediatrics, Dongying People's Hospital, Dongying, Shandong 257000, P.R. China, Department of Nutrition, Dongying People's Hospital, Dongying, Shandong 257000, P.R. China
Published online on: October 21, 2016 https://doi.org/10.3892/etm.2016.3831
Pages: 3579-3582
Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The effects of recombinant human growth hormone (rhGH) in the treatment of dwarfism and the relationship between insulin-like growth factor (IGF)-1, IGF-binding protein (IGFBP)-3 and thyroid hormone were examined in the present study. For this purpose, 66 patients diagnosed with dwarfism were selected retrospectively, with 36 cases of growth hormone deficiency (GHD) and 30 cases of idiopathic short stature (ISS). The therapeutic dose of GHD 0.10 IU/kg·day and ISS 0.15 IU/kg·day were injected subcutaneously every night before sleep until adulthood. The average follow-up was 5 years, and the results were evaluated and measured every 3 months, including height, BA, secondary test of growth hormone (GH peak), IGF-1, IGFBP-3 and thyroid hormone (FT3, FT4 and TSH). After treatment, the height, BA, GH peak, IGF-A and IGFBP-3 of the GHD group were all increased, and the differences were statistically significant (P<0.05), while FT3, FT4 and TSH had no significant change (P<0.05). The height and BA increased and the differences were statistically significant (P<0.05). The indexes of the ISS group were not statistically significant (P>0.05). The results of the Pearson‑related analysis suggested that GH peak of the GHD group, IGF-1 and IGFBP-3 were positively associated with height (P<0.05), and had no relationship with BA (P<0.05). None of the above indexes of the ISS group had an obvious correlation with height and BA (P>0.05). rhGH was effective for GHD and ISS, with the GHD effect being positively associated with the GH peak, IGF-1 and IGFBP-3. ISS had no obvious relationship with GH peak, IGF-1 and IGFBP-3 although other influencing factors may be involved.

View Figures

View References

1	Iglesias P and Díez JJ: Clinical applications of recombinant human growth hormone in adults. Expert Opin Pharmacother. 1:97–107. 1999. View Article : Google Scholar : PubMed/NCBI
2	Sassolas G: Potential therapeutic applications of growth hormone in adults. Horm Res. 42:72–78. 1994. View Article : Google Scholar : PubMed/NCBI
3	Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown R, Hardin DS, Kemp SF, Lawson M, Radovick S, et al: Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee: Update of guidelines for the use of growth hormone in children: The Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr. 143:415–421. 2003. View Article : Google Scholar : PubMed/NCBI
4	Growth Hormone Research Society; GH Research Society, . Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab. 85:3990–3993. 2000. View Article : Google Scholar : PubMed/NCBI
5	Gharib H, Cook DM, Saenger PH, Bengtsson BA, Feld S, Nippoldt TB, Rodbard HW, Seibel JA, Vance ML and Zimmerman D: American Association of Clinical Endocrinologists Growth Hormone Task Force: American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children - 2003 update. Endocr Pract. 9:64–76. 2003. View Article : Google Scholar : PubMed/NCBI
6	Teran E, Chesner J and Rapaport R: Growth and growth hormone: an overview. Growth Horm IGF Res. 28:3–5. 2016. View Article : Google Scholar : PubMed/NCBI
7	Albertsson-Wikland K: Growth hormone therapy needs to be tailored based on individual responsiveness in children with idiopathic short stature. J Pediatr. 159:5162011. View Article : Google Scholar : PubMed/NCBI
8	Liu Z, Mohan S and Yakar S: Does the GH/IGF-1 axis contribute to skeletal sexual dimorphism? Evidence from mouse studies. Growth Horm IGF Res. 27:7–17. 2016. View Article : Google Scholar : PubMed/NCBI
9	Hawkes CP and Grimberg A: Insulin-like growth factor-I is a marker for the nutritional state. Pediatr Endocrinol Rev. 13:499–511. 2015.PubMed/NCBI
10	Gaspari L, Paris F, Leboucq N, Bonafé A and Sultan C: Reversible growth failure and complete GH deficiency in a 4-year-old girl with very early Hashimoto's thyroiditis and subsequent hyperplasia of pituitary thyrotroph cells. Eur J Pediat. Feb 2–2016.(Epub ahead of print). View Article : Google Scholar
11	Inzaghi E and Cianfarani S: The challenge of growth hormone deficiency diagnosis and treatment during the transition from puberty into adulthood. Front Endocrinol (Lausanne). 4:342013.PubMed/NCBI
12	Cook DM, Yuen KC, Biller BM, Kemp SF and Vance ML: American Association of Clinical Endocrinologists: American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update: executive summary of recommendations. Endocr Pract. 15:580–586. 2009. View Article : Google Scholar : PubMed/NCBI
13	Ho KK: 2007 GH Deficiency Consensus Workshop Participants: Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 157:695–700. 2007. View Article : Google Scholar : PubMed/NCBI
14	Molitch ME, Clemmons DR, Malozowski S, Merriam GR and Vance ML: Endocrine Society: Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 96:1587–1609. 2011. View Article : Google Scholar : PubMed/NCBI
15	Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM and Tauber M: European Society of Paediatric Endocrinology: Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol. 152:165–170. 2005. View Article : Google Scholar : PubMed/NCBI
16	Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T and Lippe B: Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 95:167–177. 2010. View Article : Google Scholar : PubMed/NCBI
17	Tritos NA and Klibanski A: Effects of growth hormone on bone. Prog Mol Biol Transl Sci. 138:193–211. 2016. View Article : Google Scholar : PubMed/NCBI
18	Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO and Wit JM: 2007 ISS Consensus Workshop participants: Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 93:4210–4217. 2008. View Article : Google Scholar : PubMed/NCBI
19	Salerno M, Balestrieri B, Matrecano E, Officioso A, Rosenfeld RG, Di Maio S, Fimiani G, Ursini MV and Pignata C: Abnormal GH receptor signaling in children with idiopathic short stature. J Clin Endocrinol Metab. 86:3882–3888. 2001. View Article : Google Scholar : PubMed/NCBI